BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...

Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Therapeutics announced topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular ...

The following is a summary of “Microcystoid macular edema in epiretinal membrane: not a retrograde maculopathy,” published in ...

Drug-induced lung disease cases in France mostly involved ILD, pulmonary edema, and pulmonary fibrosis, largely linked to cancer and CV drugs.

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...